OR WAIT null SECS
May 12, 2022
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
May 10, 2022
Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.
April 25, 2022
Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.
April 18, 2022
Researchers found that patients with nAMD lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.
April 07, 2022
Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.
April 01, 2022
This latest approval for Beovu (brolucizumab) 6 mg is the second indication granted by the EC, as it was first approved in 2020 for the treatment of AMD.
January 28, 2022
Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.
Q&A: Pandemic's effect on dry eye patient numbers
Pearls on diagnosing and managing glaucoma for optometrists
Q&A: Factors to consider when treating dry eye patients
Q&A: How to start the dry eye conversation with patients
